Clinical trial · Observational
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
NCT02819882CI-TRIAL-00107498REGISTEMrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a prospective, multicenter non-interventional cohort study designed to develop a registry in unresectable locally advanced or metastatic disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Luminal A-like subtype
- description
- Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (\< 14%).
- interventionNames
- Other: No intervention
- label
- Luminal B-like (HER2 negative) subtype:
- description
- Patients that express ER and are either PgR- or low (\< 20%) and/or Ki67 'high' (≥ 14%).
- interventionNames
- Other: No intervention
- label
- Luminal B-like (HER2 positive) subtype:
- description
- Patients that express ER and HER2 irrespective of PgR or Ki67 status.
- interventionNames
- Other: No intervention
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients (males or females) diagnosed with unresectable locally advanced or MBC (either after a recurrence or as first diagnosis) from January 2016 onwards. 2. Patients who died are allowed to be included on the study. 3. Able and willing to provide written informed consent if they are alive. 4. Age ≥ 18 years. 5. Availability to medical records access and all data related to the disease management. Exclusion Criteria: None
References
Publications (0)
Data not yet available
No reference posted for this study.